Pharmathene, Inc. (f/k/a PIP)

[surf1944]

9:20AM PharmAthene announces the FDA lifted the clinical hold previously placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine (PIP) 1.81 : Co annouces the FDA has lifted the clinical hold previously placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine.

In a letter to the Company, the FDA acknowledged that PharmAthene had satisfactorily addressed all of the Agency's clinical hold issues and that consequently, the clinical hold had been lifted, effective immediately.